Our vision is to overcome obesity.

Lasker~DeBakey Award 2024 for groundbreaking GLP-1 obesity research

GLP-1 weight loss drugs like Wegovy are attracting startups and investors, aiming to tap into the projected $150bn market despite supply and reimbursement challenges

Four foods that should come with a smoking-style health warning Some scientists believe ultra-processed food needs to be treated in a similar way to tobacco.

Join Health Tech World's webinar with experts discussing sustainable weight loss through medication, lifestyle changes, and digital health tools. Watch now!

Study shows GLP-1 agonists reduce dementia risk in elderly with type 2 diabetes. Findings from KI highlight potential benefits for diabetes treatment

Medical Product Alert: Fake Ozempic (semaglutide) Detected in Americas and Europe

Wigan named UK's 'Fattest Town' - Yazen Health tackles obesity safely

Dr. Punam Krishan debunks myths surrounding obesity

The obesity epidemic is one of the greatest health challenges of our time. Globally, it is estimated that 1.9 billion people will suffer from morbid obesity by 2035, which represents one in four adults. Among children, obesity is expected to increase by 100 percent between 2020 and 2035. The cost to society is projected to be 4 trillion dollars.

Martin Carlsson participates in "Where next for digital health? A roundtable debate hosted by Health Tech World

Yazen tackles the challenge with groundbreaking, accessible, and comprehensive treatment approach

Weight-loss injections like Ozempic and Wegovy have gained significant attention, European startups entering market

Patients at the digital healthcare provider Yazen have now collectively shed 60 tonnes